A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Status
Active
Cancer Type
Lung Cancer
Trial Phase
Phase III
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT02486718
Protocol IDs
GO29527 (primary)
NCI-2015-01731
Study Sponsor
Hoffmann-La Roche

Summary

The primary efficacy objective of the study is to evaluate the efficacy of 16 cycles of

Atezolizumab (MPDL3280A) treatment compared with best supportive care as measured by

disease-free survival (DFS) as assessed by the investigator